In yesterday’s Wall Street session, Puma Biotechnology Inc (NASDAQ:PBYI) shares traded at $4.14, up 7.53% from the previous session.
3 analysts cover Puma Biotechnology Inc (NASDAQ:PBYI), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.00, we find $4.00. Given the previous closing price of $3.85, this indicates a potential upside of 3.9 percent. PBYI stock price is now 46.33% away from the 50-day moving average and 29.81% away from the 200-day moving average. The market capitalization of the company currently stands at $196.94M.
The stock has received a hold rating from 1 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $4.67 as their price target over the next twelve months.
With the price target maintained at $11, Citigroup recently Upgraded its rating from Neutral to Buy for Puma Biotechnology Inc (NASDAQ: PBYI).
In other news, MILLER MICHAEL PATRICK, Director sold 25,000 shares of the company’s stock on Nov 07. The stock was sold for $70,802 at an average price of $2.83. Upon completion of the transaction, the Director now directly owns 43,358 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 03, President and CEO AUERBACH ALAN H sold 60,698 shares of the business’s stock. A total of $200,983 was realized by selling the stock at an average price of $3.31. This leaves the insider owning 6,978,343 shares of the company worth $28.89 million. Insiders disposed of 266,243 shares of company stock worth roughly $1.1 million over the past 1 year. A total of 22.06% of the company’s stock is owned by insiders.
On Wednesday morning Puma Biotechnology Inc (NASDAQ: PBYI) stock kicked off with the opening price of $3.8500. During the past 12 months, Puma Biotechnology Inc has had a low of $2.13 and a high of $5.16. As of last week, the company has a debt-to-equity ratio of 2.90, a current ratio of 1.86, and a quick ratio of 1.78. The fifty day moving average price for PBYI is $2.8292 and a two-hundred day moving average price translates $3.1892 for the stock.
The latest earnings results from Puma Biotechnology Inc (NASDAQ: PBYI) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.12, beating analysts’ expectations of $0.08 by 0.04. This compares to -$0.01 EPS in the same period last year. The net profit margin was 1.62% and return on equity was 12.21% for PBYI. The company reported revenue of $56.12 million for the quarter, compared to $57.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.73 percent. For the current quarter, analysts expect PBYI to generate $73.55M in revenue.
Puma Biotechnology Inc(PBYI) Company Profile
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company’s drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
